Moviprep (Ascorbic Acid, Sodium Ascorbate, Potassium Chloride, Sodium Chloride, Sodium Sulfate Anhydrous, Macr)

The polyethylene glycol 3350 component is a large, non‑absorbable polymer that retains water in the intestinal lumen by osmosis. The added electrolytes (sodium, potassium, chloride, sulfate) maintain fluid balance, while ascorbic acid enhances the osmotic gradient, together facilitating rapid bowel evacuation.

The prescribed dose of Moviprep is individualized by the treating physician based on the patient’s age, weight, renal function, and the specific endoscopic procedure. The healthcare professional calculates the total volume of powder to be reconstituted and the timing of ingestion according to the product’s label instructions.

The safety of Moviprep in pregnancy or lactation has not been definitively established. It should only be used when the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider after evaluating the clinical situation.

To place an order, visit the product page on gnhindia.com, enter the required quantity, and submit the enquiry form. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Compared with sodium‑picosulfate‑based or magnesium‑oxide preparations, Moviprep provides a balanced electrolyte solution and a rapid, high‑volume osmotic effect, which can result in more consistent colon cleansing. However, the larger fluid volume may be less convenient for some patients, and individual tolerance varies.

Store Moviprep at ambient temperature, preferably below 25 °C, in its original sealed container. Protect the powder from moisture and direct sunlight. Do not refrigerate or freeze the product, as temperature extremes can affect its stability and efficacy.

Moviprep is supplied as a powder that must be dissolved in a specified volume of water to create an oral solution. The patient drinks the solution in divided doses as directed by the prescribing physician, usually the evening before and the morning of the procedure, while maintaining adequate fluid intake.

The most serious adverse events include severe dehydration, electrolyte disturbances (such as hyponatremia or hypokalemia), and rare cases of acute renal impairment. Patients should be monitored for signs of excessive fluid loss, dizziness, muscle cramps, or abnormal heart rhythms, and seek medical attention promptly if they occur.

Moviprep is contraindicated in individuals with known or suspected intestinal obstruction, perforation, severe inflammatory bowel disease, or significant renal impairment. It should also be avoided in patients with uncontrolled electrolyte imbalances or hypersensitivity to any of its components. A healthcare professional must assess suitability before prescribing.